We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) ...
Jefferies double downgraded Opthea (OPT) to Underperform from Buy with a price target of $1, down from $8, after the company announced that its ...
H.C. Wainwright analyst Matthew Caufield downgraded Opthea (OPT) to Neutral from Buy with a price target of $2, down from $12 after the Phase 3 ...
UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical ...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...
We recently published a list of 11 Best Extremely Profitable Stocks to Buy According to Analysts. In this article, we are ...
The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Comcast ...
Building upon its already impressive obesity drug portfolio, Novo Nordisk A/S has licensed a triple agonist of the receptors for GLP-1, GIP and glucagon from United Biotechnology Co. Ltd. China-based ...
The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...
Australia-based Opthea, a biopharma developing therapies for progressive retinal diseases, has announced results from its ...
Opthea's sozinibercept and Unity's UBX1325 fail to match Regeneron's Eylea in separate eye disease trials; Opthea faces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback